

Table 1: List of women enrolled in both clinical trials and side effects.

N°	Age	Cervix	HPV type	Viral load		Side effects	
				BT	AT	General effects	Inflammation
C1	20	N	ND	ND	ND	NR	NR
C2	20	N	ND	ND	ND	NR	NR
C3	19	N	ND	ND	ND	NR	NR
C4	33	N	ND	ND	ND	NR	NR
C5	21	N	ND	ND	ND	NR	NR
C6	26	N	ND	ND	ND	NR	NR
C7	22	N	ND	ND	ND	NR	NR
C8	24	N	ND	ND	ND	NR	NR
C9	25	N	ND	ND	ND	NR	NR
C10	25	N	ND	ND	ND	NR	NR
C11	22	N	ND	ND	ND	NR	NR
G1	41	LSIL	59/70	21	0	NR	NR
G2	34	LSIL	35	955	0	Headache, genital pain, dyspareunia, urinary disorders	NR
G3	33	LSIL	18	11	0	NR	ND
G4	45	LSIL	16/31/53	1183	233	NR	Mild and transient
G5	41	LSIL	16/56/66	74	820	NR	Mild and transient
G6	36	LSIL	56/59/66	37	ND	NR	NR
G7	29	LSIL	43/44- 55/52	30	ND	NR	NR
G8	47	LSIL	42/44- 55/52/53/70	133	9	NR	Mild and transient
G9	35	LSIL	53/56	4	77	NR	ND
G10	31	LSIL	16/52	410	1421	NR	NR
P1	27	LSIL	31/44- 55/53 (18*)	37	12	NR	NR
P2	30	LSIL	39	703	8	NR	NR
P3	37	LSIL	68	7	0	NR	NR
P4	21	LSIL	56/66	40	147	NR	NR
P5	29	LSIL	66	6	1	Genital pain	Mild and transient

C1-C11 women from phase Ia clinical trial, G1-G10 patients from phase Ib clinical trial receiving GM-CSF; P1-P5 placebo patient from phase Ib clinical trial. * Only positive for HPV18 with specific PCR. BT= before treatment; AT = after treatment; NR = not reported; ND not determined.